IsoRay (NYSEAMERICAN:ISR) issued its earnings results on Thursday. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02), Morningstar.com reports. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $1.73 million.
NYSEAMERICAN ISR traded down $0.05 during trading hours on Friday, reaching $0.39. 806,773 shares of the company were exchanged, compared to its average volume of 628,840. IsoRay has a 1 year low of $0.36 and a 1 year high of $1.22.
Several brokerages recently issued reports on ISR. Maxim Group lowered shares of IsoRay from a “buy” rating to a “hold” rating in a research note on Friday. Zacks Investment Research raised shares of IsoRay from a “sell” rating to a “hold” rating in a research note on Friday. Finally, HC Wainwright set a $1.00 target price on shares of IsoRay and gave the stock a “hold” rating in a research note on Wednesday, September 26th.
IsoRay Company Profile
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Read More: Balance Sheet
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.